Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00720109 · OUTCOME

Overall EFS Rate for the Combined Cohort of Standard- and High-Risk Patients (Who Receive the Final Chosen Dose of Dasatinib)

Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia · Source last updated 2020-04-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of patients
Interval / dispersion
90% Confidence Interval
Time frame
From the time entry on study to first event or date of last follow-up, assessed up to 7 years

What was measured

An event is defined as: Induction failure, relapse at any site, secondary malignancy, or death.

Analysis population: Included in the analysis are two patients who received the drug therapy but were not risk classified.

Groups in this outcome

Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy)

See Detailed Description Asparaginase: Given IT Cyclophosphamide: Given IV Cytarabine: Given IT or IV Dasatinib: Given PO Daunorubicin Hydrochloride: Given IV Dexamethasone: Given IV or PO Etoposide: Given IV Filgrastim: Given IV or SC Hydrocortisone Sodium Succinate: Given IT Ifosfamide: Given IV Laboratory Biomarker Analysis: Correlative studies Leucovorin Calcium: Given IV or PO Mercaptopurine: Given PO Methotrexate: Given IT, PO, or IV Methylprednisolone: Given IV Pegaspargase: Given IM Prednisone: Given PO or IV Radiation Therapy: Some patients undergo cranial RT Vincristine Sulfate: Given IV

Standard-risk

Based on Minimal Residual Disease, less than 1%.

High-risk

Based on Minimal Residual Disease, great than or equal to 1%.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy)60
Standard-risk48
High-risk9

Reported measurements

Source class 1
Values in percentage of patients · Interval/dispersion: 90% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy)79.8Not reported71.188.5Not reported
Standard-risk83.2Not reported74.192.2Not reported
High-risk66.7Not reported40.992.5Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        71.1
        upper Limit
        88.5
        value
        79.8
      2. group Id
        OG001
        lower Limit
        74.1
        upper Limit
        92.2
        value
        83.2
      3. group Id
        OG002
        lower Limit
        40.9
        upper Limit
        92.5
        value
        66.7
denoms
  1. counts
    1. group Id
      OG000
      value
      60
    2. group Id
      OG001
      value
      48
    3. group Id
      OG002
      value
      9
    units
    Participants
description
An event is defined as: Induction failure, relapse at any site, secondary malignancy, or death.
dispersion Type
90% Confidence Interval
groups
  1. description
    See Detailed Description Asparaginase: Given IT Cyclophosphamide: Given IV Cytarabine: Given IT or IV Dasatinib: Given PO Daunorubicin Hydrochloride: Given IV Dexamethasone: Given IV or PO Etoposide: Given IV Filgrastim: Given IV or SC Hydrocortisone Sodium Succinate: Given IT Ifosfamide: Given IV Laboratory Biomarker Analysis: Correlative studies Leucovorin Calcium: Given IV or PO Mercaptopurine: Given PO Methotrexate: Given IT, PO, or IV Methylprednisolone: Given IV Pegaspargase: Given IM Prednisone: Given PO or IV Radiation Therapy: Some patients undergo cranial RT Vincristine Sulfate: Given IV
    id
    OG000
    title
    Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy)
  2. description
    Based on Minimal Residual Disease, less than 1%.
    id
    OG001
    title
    Standard-risk
  3. description
    Based on Minimal Residual Disease, great than or equal to 1%.
    id
    OG002
    title
    High-risk
param Type
NUMBER
population Description
Included in the analysis are two patients who received the drug therapy but were not risk classified.
reporting Status
POSTED
time Frame
From the time entry on study to first event or date of last follow-up, assessed up to 7 years
title
Overall EFS Rate for the Combined Cohort of Standard- and High-Risk Patients (Who Receive the Final Chosen Dose of Dasatinib)
type
SECONDARY
unit Of Measure
percentage of patients

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice